Iloprost-d4
(Synonyms: Ciloprost-d4) 目录号 : GC91752Iloprost-d4 is intended for use as an internal standard for the quantification of iloprost by GC- or LC-MS.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Iloprost-d4 is intended for use as an internal standard for the quantification of iloprost by GC- or LC-MS. Iloprost is an agonist of the IP receptor and the prostaglandin E2 (PGE2) receptor subtype EP1 and a derivative of PGI2.[1],[2] It selectively binds to IP and EP1 receptors (Ki = 11 nM for both) over EP2, EP4, DP, FP, and TP receptors (Kis = 1,870, 284, 1,035, 619, and 6,487 nM, respectively) but also binds to the EP3 receptor (Ki = 56 nM).[1] Iloprost increases cAMP levels in HEK293 cells expressing IP or EP3 receptors (EC50s = 0.37 and 27.5 nM, respectively) and increases calcium levels in HEK293 cells expressing the EP1 receptor (EC50 = 0.3 nM).[2] It inhibits ADP-, thrombin-, and collagen-induced platelet aggregation in isolated human platelet-rich plasma (IC50s = 1.07, 0.71, and 0.24 nM, respectively).[3] Iloprost (100 ng/kg per minute) increases the time to occlusive coronary artery thrombosis in a porcine model of electrically induced coronary artery thrombosis.[4] Aerosolized administration of iloprost (130-1,300 ng/kg per minute) reduces right ventricular systolic pressure and reverses vascular remodeling in rats in a model of chronic pulmonary hypertension induced by the alkaloid monocrotaine .[5] Formulations containing iloprost have been used in the treatment of pulmonary arterial hypertension and severe frostbite.
References:
[1].Abramovitz, M., Adam, M., Boie, Y., et al.The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogsBiochim. Biophys. Acta1483(2)285-293(2000).
[2].Whittle, B.J., Silverstein, A.M., Mottola, D.M., et al.Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonistBiochem. Pharmacol.84(1)68-75(2012).
[3].Schrör, K., Darius, H., Matzky, R., et al.The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK36374) — equipotent to PGI2 in vitroNaunyn Schmiedebergs Arch. Pharmacol.316(3)252-255(1981).
[4].van der Giessen, W.J., Mooi, W.J., Rutteman, A.M., et al.The effect of the stable prostacyclin analogue ZK 36374 on experimental coronary thrombosis in the pigThromb. Res.36(1)45-51(1984).
[5].Schermuly, R.T., Yilmaz, H., Ghofrani, H.A., et al.Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertensionAm. J. Respir. Crit. Care Med.172(3)358-363(2005).
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7435 mL | 13.7174 mL | 27.4348 mL |
| 5 mM | 0.5487 mL | 2.7435 mL | 5.487 mL |
| 10 mM | 0.2743 mL | 1.3717 mL | 2.7435 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。